Log in

NASDAQ:RGNX - Regenxbio Stock Price, Forecast & News

$33.88
+1.34 (+4.12 %)
(As of 03/29/2020 03:01 PM ET)
Today's Range
$30.23
Now: $33.88
$34.56
50-Day Range
$21.50
MA: $41.02
$54.20
52-Week Range
$20.03
Now: $33.88
$59.98
Volume547,415 shs
Average Volume724,173 shs
Market Capitalization$1.26 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.88
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trials for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trials to treat mucopolysaccharidosis type II; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. The company was formerly known as REGENX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Read More
Regenxbio logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RGNX
CUSIPN/A
Phone240-552-8181

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$35.23 million
Book Value$12.23 per share

Profitability

Net Income$-94,730,000.00
Net Margins-268.88%

Miscellaneous

Employees192
Market Cap$1.26 billion
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive RGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for RGNX and its competitors with MarketBeat's FREE daily newsletter.


Regenxbio (NASDAQ:RGNX) Frequently Asked Questions

How has Regenxbio's stock been impacted by COVID-19 (Coronavirus)?

Regenxbio's stock was trading at $32.89 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, RGNX stock has increased by 3.0% and is now trading at $33.88. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Regenxbio?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regenxbio in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Regenxbio.

When is Regenxbio's next earnings date?

Regenxbio is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Regenxbio.

How were Regenxbio's earnings last quarter?

Regenxbio Inc (NASDAQ:RGNX) announced its quarterly earnings data on Wednesday, February, 26th. The biotechnology company reported ($0.72) EPS for the quarter, missing analysts' consensus estimates of ($0.44) by $0.28. The biotechnology company had revenue of $11.77 million for the quarter, compared to analyst estimates of $39.67 million. Regenxbio had a negative return on equity of 25.21% and a negative net margin of 268.88%. View Regenxbio's earnings history.

What price target have analysts set for RGNX?

5 brokerages have issued twelve-month target prices for Regenxbio's shares. Their forecasts range from $37.00 to $150.00. On average, they expect Regenxbio's stock price to reach $76.75 in the next year. This suggests a possible upside of 126.5% from the stock's current price. View analysts' price targets for Regenxbio.

Has Regenxbio been receiving favorable news coverage?

Media headlines about RGNX stock have been trending positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Regenxbio earned a coverage optimism score of 2.7 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutRegenxbio.

Who are some of Regenxbio's key competitors?

What other stocks do shareholders of Regenxbio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regenxbio investors own include NVIDIA (NVDA), Amarin (AMRN), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Micron Technology (MU), AbbVie (ABBV), Intercept Pharmaceuticals (ICPT), Visa (V), Advanced Micro Devices (AMD) and Voyager Therapeutics (VYGR).

Who are Regenxbio's key executives?

Regenxbio's management team includes the following people:
  • Mr. Kenneth T. Mills, CEO, Pres & Director (Age 44)
  • Mr. Vittal K. Vasista, Chief Financial Officer (Age 51)
  • Mr. Curran M. Simpson, Sr. VP of Product Devel. & Chief Technology Officer (Age 57)
  • Dr. Olivier Danos, Chief Scientific Officer (Age 61)
  • Dr. Stephen Yoo, Consultant (Age 41)

What is Regenxbio's stock symbol?

Regenxbio trades on the NASDAQ under the ticker symbol "RGNX."

Who are Regenxbio's major shareholders?

Regenxbio's stock is owned by a number of institutional and retail investors. Top institutional shareholders include State Street Corp (5.10%), UBS Group AG (1.78%), Credit Suisse AG (1.38%), Kam Lawrence (1.27%), Geode Capital Management LLC (1.25%) and Korea Investment CORP (1.24%). Company insiders that own Regenxbio stock include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Luke M Beshar, Olivier Danos, Patrick J Christmas, Stephen Yoo and Vittal Vasista. View institutional ownership trends for Regenxbio.

Which institutional investors are selling Regenxbio stock?

RGNX stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Rafferty Asset Management LLC, Bank of New York Mellon Corp, Citigroup Inc., SG Americas Securities LLC, Nuveen Asset Management LLC, P.A.W. Capital Corp, and AQR Capital Management LLC. Company insiders that have sold Regenxbio company stock in the last year include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Olivier Danos, Patrick J Christmas, and Vittal Vasista. View insider buying and selling activity for Regenxbio.

Which institutional investors are buying Regenxbio stock?

RGNX stock was acquired by a variety of institutional investors in the last quarter, including Kam Lawrence, Norges Bank, UBS Group AG, Goldman Sachs Group Inc., Barclays PLC, Parkman Healthcare Partners LLC, Panagora Asset Management Inc., and Rhenman & Partners Asset Management AB. View insider buying and selling activity for Regenxbio.

How do I buy shares of Regenxbio?

Shares of RGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Regenxbio's stock price today?

One share of RGNX stock can currently be purchased for approximately $33.88.

How big of a company is Regenxbio?

Regenxbio has a market capitalization of $1.26 billion and generates $35.23 million in revenue each year. The biotechnology company earns $-94,730,000.00 in net income (profit) each year or ($3.26) on an earnings per share basis. Regenxbio employs 192 workers across the globe. View additional information about Regenxbio.

What is Regenxbio's official website?

The official website for Regenxbio is http://www.regenxbio.com/.

How can I contact Regenxbio?

Regenxbio's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-552-8181 or via email at [email protected]


MarketBeat Community Rating for Regenxbio (NASDAQ RGNX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  367 (Vote Outperform)
Underperform Votes:  317 (Vote Underperform)
Total Votes:  684
MarketBeat's community ratings are surveys of what our community members think about Regenxbio and other stocks. Vote "Outperform" if you believe RGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel